Why centralized logistics are failing and how MovitOn picks up the package

The monolithic, centralized model has been used to move goods globally for years, with giants like FedEx, DHL, and UPS building their empires on promises of reliability that show severe stress fractures.  The traditional logistics paradigm is expensive, rigid, and increasingly disconnected from the fluid reality of modern commerce. It is a system built for… Continue reading Why centralized logistics are failing and how MovitOn picks up the package

China’s YMTC eyes expansion with two new chip plants

Chinese memory chipmaker Yangtze Memory Technologies is planning to build two additional factories alongside one nearing completion, a move that could more than double its production capacity. The expansion comes as China continues its push to reduce reliance on foreign semiconductor technologies, a sector where the United States has imposed restrictions to curb Beijing’s progress.… Continue reading China’s YMTC eyes expansion with two new chip plants

Dow futures surge 100 points: 5 things to know before market opens

US stock index futures edged higher on Tuesday as investors weighed tentative signs of de-escalation between Washington and Tehran against a macro backdrop that remains uneasy. The mood turned more measured, as Washington moved to enforce a maritime blockade targeting Iran-linked traffic, while oil prices retreated from earlier highs on cautious optimism. Nearly two dozen… Continue reading Dow futures surge 100 points: 5 things to know before market opens

Citi, BlackRock upgrade US equities on strong earnings, easing war risks

Even as global markets grapple with volatility triggered by the Iran war and sharp swings in oil prices, a growing number of brokerages and asset managers are turning constructive on US equities. Analysts point to resilient corporate earnings, improving valuations after recent corrections and the outsized role of technology companies in driving global profit growth… Continue reading Citi, BlackRock upgrade US equities on strong earnings, easing war risks

Givaudan beats sales estimates as fragrance demand lifts shares

Swiss fragrance and flavour maker Givaudan reported stronger-than-expected first-quarter sales growth, supported by robust demand in its fragrance and consumer products segment. The company said its LFL sales rose 2.8% in the quarter. This excludes the impact of currency fluctuations, acquisitions, and disposals. This figure came in above a company-compiled consensus forecast of 1.9%. Analysts… Continue reading Givaudan beats sales estimates as fragrance demand lifts shares

Top reasons a United Airlines and American merger is unlikely to happen

The United Airlines (UAL) and American Airlines (AAL) stocks will be in the spotlight today, April 14, as investors react to news of a potential mega-merger. AAL has dropped to $11.25, down by over 30% from its highest point last year. Similarly, United Airlines has dropped to $95, down by 20% from the same period… Continue reading Top reasons a United Airlines and American merger is unlikely to happen

What’s behind BP’s exceptional Q1 forecast, and debt surge with it?

BP is heading into its first-quarter results with an unusually strong message on earnings, but also with a less comfortable one on the balance sheet. The oil major said on Tuesday that its oil trading business is expected to deliver “exceptional” results in the first quarter. The forecasts are helped by the violent swings that… Continue reading What’s behind BP’s exceptional Q1 forecast, and debt surge with it?

Novo Nordisk taps OpenAI to boost AI in drug development

Novo Nordisk on Tuesday announced a partnership with OpenAI to deploy artificial intelligence across its business, spanning drug discovery, manufacturing and commercial operations, as the Danish drugmaker looks to sharpen its competitive edge in the fast-growing obesity drug market. The company said the collaboration would leverage OpenAI’s technology to analyse complex datasets, identify promising drug… Continue reading Novo Nordisk taps OpenAI to boost AI in drug development

Why is OpenAI’s $852B valuation facing investor scrutiny?

OpenAI’s massive $852 billion valuation is coming under scrutiny from some of its own investors as the company pivots its focus toward enterprise offerings, according to a report by the Financial Times published on Tuesday. The concerns emerge as the company pivots towards enterprise-focused offerings in an effort to counter rising competition. The shift in… Continue reading Why is OpenAI’s $852B valuation facing investor scrutiny?